NATEC Medical Ltd and US Endovascular collaborate to deliver a brand new PTA generation to the peripheral US market.
Peripheral Arterial Disease(PAD) is the narrowing or blockage of the vessels that carry blood fromthe heart to the organs. It is primarily caused by the build-up of fatty plaque in the arteries, which is called atherosclerosis. PAD can occur in any blood vessel, but it is more common in the legs than the arms.
- PAD affects 12 to 14% of the general population.
- PAD affects 20% of patients over the age of 75.
- Over 27 million people in the U.S. and Europe are estimated to have PAD.
- 220,000-240,000 amputations per year in the U.S./Europe.
- 49% of those amputations had no diagnostic testing for PAD.
NATEC Medical Ltd is pleased to announce an exclusive collaboration with US Endovascular to deliver on US market a brand new range of PTA balloon catheters.This new balloon technology is specifically engineered to address more complex peripheral artery disease (PAD), giving physicians the potential to treat more patients, with better outcomes, as well as potentially decrease the need for additional peripheral angioplasty devices. USEndovascular will launch 3 different PTA platforms:
- USE 014” Rapid Exchange (Rx) and Over The Wire (OTW)
- USE 018” OTW
- USE 035” OTW
Size range from 20 to 200 mm long and 1.5 to12 mm diameter.
About NATEC Medical
NATEC Medical Ltd is a Mauritius based PTCA and PTA balloon catheters manufacturer. NATEC Medical has proven to be the Global Partner for OEM medical devices market including Drug Eluting Balloon platforms, to prestigious clients who place their trust in our expertise and quality products. New orientations are driven by strategic business alliances, extended product portfolios and new value services, amongst which a complete crimping department with all the latest machines available. NATECM edicalisa privately held company.
About US Endovascular
US Endovascular is based in St.Louis, Mo. US Endovascular is committed to providing high quality cutting edge technology to the Endovascular and Coronary market with an appreciable cost reduction to the end user. US Endovascular was founded in 2014, John McCurdy, Joel Crater and David Gardner are graduates of the University of Missouri-Columbia.
Miroslav SECEROV – VP Sales&Marketing
Ebène Business Park